Format
Sort by
Items per page

Send to

Choose Destination

Best matches for Färkkilä A[au]:

Pathogenesis and treatment of adult-type granulosa cell tumor of the ovary. Färkkilä A et al. Ann Med. (2017)

GATA factors in endocrine neoplasia. Pihlajoki M et al. Mol Cell Endocrinol. (2016)

The Fanconi Anemia Pathway in Cancer. Niraj J et al. Annu Rev Cancer Biol. (2019)

Search results

Items: 31

1.

Open Source Infrastructure for Health Care Data Integration and Machine Learning Analyses.

Isoviita VM, Salminen L, Azar J, Lehtonen R, Roering P, Carpén O, Hietanen S, Grénman S, Hynninen J, Färkkilä A, Hautaniemi S.

JCO Clin Cancer Inform. 2019 Aug;3:1-16. doi: 10.1200/CCI.18.00132.

2.

The CHK1 Inhibitor Prexasertib Exhibits Monotherapy Activity in High-Grade Serous Ovarian Cancer Models and Sensitizes to PARP Inhibition.

Parmar K, Kochupurakkal BS, Lazaro JB, Wang ZC, Palakurthi S, Kirschmeier PT, Yang C, Sambel LA, Färkkilä A, Reznichenko E, Reavis HD, Dunn CE, Zou L, Do KT, Konstantinopoulos PA, Matulonis UA, Liu JF, D'Andrea AD, Shapiro GI.

Clin Cancer Res. 2019 Oct 15;25(20):6127-6140. doi: 10.1158/1078-0432.CCR-19-0448. Epub 2019 Aug 13.

PMID:
31409614
3.

Single-Arm Phases 1 and 2 Trial of Niraparib in Combination With Pembrolizumab in Patients With Recurrent Platinum-Resistant Ovarian Carcinoma.

Konstantinopoulos PA, Waggoner S, Vidal GA, Mita M, Moroney JW, Holloway R, Van Le L, Sachdev JC, Chapman-Davis E, Colon-Otero G, Penson RT, Matulonis UA, Kim YB, Moore KN, Swisher EM, Färkkilä A, D'Andrea A, Stringer-Reasor E, Wang J, Buerstatte N, Arora S, Graham JR, Bobilev D, Dezube BJ, Munster P.

JAMA Oncol. 2019 Jun 13. doi: 10.1001/jamaoncol.2019.1048. [Epub ahead of print]

4.

The Fanconi Anemia Pathway in Cancer.

Niraj J, Färkkilä A, D'Andrea AD.

Annu Rev Cancer Biol. 2019 Mar;3:457-478. doi: 10.1146/annurev-cancerbio-030617-050422. Epub 2018 Dec 3.

5.

Other Primary Malignancies Among Women With Adult-Type Ovarian Granulosa Cell Tumors.

Bryk S, Pukkala E, Färkkilä A, Heikinheimo M, Unkila-Kallio L, Riska A.

Int J Gynecol Cancer. 2018 Oct;28(8):1529-1534. doi: 10.1097/IGC.0000000000001333.

PMID:
30036228
6.

Correction: TERT promoter mutation in adult granulosa cell tumor of the ovary.

Pilsworth JA, Cochrane DR, Xia Z, Aubert G, Färkkilä AEM, Horlings HM, Yanagida S, Yang W, Lim JLP, Wang YK, Bashashati A, Keul J, Wong A, Norris K, Brucker SY, Taran FA, Krämer B, Staebler A, van Meurs H, Oliva E, Shah SP, Kommoss S, Kommoss F, Gilks CB, Baird DM, Huntsman DG.

Mod Pathol. 2019 Apr;32(4):593. doi: 10.1038/s41379-018-0085-8.

PMID:
29968850
7.

Evaluation of risk factors for oral infection with potential for spread in a 1-year cohort study.

Färkkilä E, Rautemaa-Richardson R, Färkkilä A, Grönholm L, Lauhio A.

Clin Oral Investig. 2019 Feb;23(2):905-911. doi: 10.1007/s00784-018-2518-7. Epub 2018 Jun 14.

PMID:
29948280
8.

A Functional Homologous Recombination Assay Predicts Primary Chemotherapy Response and Long-Term Survival in Ovarian Cancer Patients.

Tumiati M, Hietanen S, Hynninen J, Pietilä E, Färkkilä A, Kaipio K, Roering P, Huhtinen K, Alkodsi A, Li Y, Lehtonen R, Erkan EP, Tuominen MM, Lehti K, Hautaniemi SK, Vähärautio A, Grénman S, Carpén O, Kauppi L.

Clin Cancer Res. 2018 Sep 15;24(18):4482-4493. doi: 10.1158/1078-0432.CCR-17-3770. Epub 2018 Jun 1.

9.

Mathematical Modeling Predicts Response to Chemotherapy and Drug Combinations in Ovarian Cancer.

Kozłowska E, Färkkilä A, Vallius T, Carpén O, Kemppainen J, Grénman S, Lehtonen R, Hynninen J, Hietanen S, Hautaniemi S.

Cancer Res. 2018 Jul 15;78(14):4036-4044. doi: 10.1158/0008-5472.CAN-17-3746. Epub 2018 May 16.

10.

TERT promoter mutation in adult granulosa cell tumor of the ovary.

Pilsworth JA, Cochrane DR, Xia Z, Aubert G, Färkkilä AEM, Horlings HM, Yanagida S, Yang W, Lim JLP, Wang YK, Bashashati A, Keul J, Wong A, Norris K, Brucker SY, Taran FA, Krämer B, Staebler A, van Meurs H, Oliva E, Shah SP, Kommoss S, Kommoss F, Gilks CB, Baird DM, Huntsman DG.

Mod Pathol. 2018 Jul;31(7):1107-1115. doi: 10.1038/s41379-018-0007-9. Epub 2018 Feb 15. Erratum in: Mod Pathol. 2018 Jul 3;:.

11.

Pathogenesis and treatment of adult-type granulosa cell tumor of the ovary.

Färkkilä A, Haltia UM, Tapper J, McConechy MK, Huntsman DG, Heikinheimo M.

Ann Med. 2017 Aug;49(5):435-447. doi: 10.1080/07853890.2017.1294760. Epub 2017 Mar 6. Review.

PMID:
28276867
12.

Systematic drug sensitivity testing reveals synergistic growth inhibition by dasatinib or mTOR inhibitors with paclitaxel in ovarian granulosa cell tumor cells.

Haltia UM, Andersson N, Yadav B, Färkkilä A, Kulesskiy E, Kankainen M, Tang J, Bützow R, Riska A, Leminen A, Heikinheimo M, Kallioniemi O, Unkila-Kallio L, Wennerberg K, Aittokallio T, Anttonen M.

Gynecol Oncol. 2017 Mar;144(3):621-630. doi: 10.1016/j.ygyno.2016.12.016. Epub 2017 Jan 16.

PMID:
28104295
13.

Roles of human epididymis protein 4, carbohydrate antigen 125, inhibin B and anti-Müllerian hormone in the differential diagnosis and follow-up of ovarian granulosa cell tumors.

Haltia UM, Hallamaa M, Tapper J, Hynninen J, Alfthan H, Kalra B, Ritvos O, Heikinheimo M, Unkila-Kallio L, Perheentupa A, Färkkilä A.

Gynecol Oncol. 2017 Jan;144(1):83-89. doi: 10.1016/j.ygyno.2016.11.018. Epub 2016 Nov 18.

PMID:
27871721
14.

FOXL2 402C>G Mutation Can Be Identified in the Circulating Tumor DNA of Patients with Adult-Type Granulosa Cell Tumor.

Färkkilä A, McConechy MK, Yang W, Talhouk A, Ng Y, Lum A, Morin RD, Bushell K, Riska A, McAlpine JN, Gilks CB, Unkila-Kallio L, Anttonen M, Huntsman DG.

J Mol Diagn. 2017 Jan;19(1):126-136. doi: 10.1016/j.jmoldx.2016.08.005. Epub 2016 Nov 1.

PMID:
27810330
15.

Circulating levels of TNF-related apoptosis inducing-ligand are decreased in patients with large adult-type granulosa cell tumors-implications for therapeutic potential.

Färkkilä A, Zauli G, Haltia UM, Pihlajoki M, Unkila-Kallio L, Secchiero P, Heikinheimo M.

Tumour Biol. 2016 Sep;37(9):11909-11916. Epub 2016 Apr 11.

PMID:
27067438
16.

Characteristics and outcome of recurrence in molecularly defined adult-type ovarian granulosa cell tumors.

Bryk S, Färkkilä A, Bützow R, Leminen A, Tapper J, Heikinheimo M, Unkila-Kallio L, Riska A.

Gynecol Oncol. 2016 Dec;143(3):571-577. doi: 10.1016/j.ygyno.2016.10.002. Epub 2016 Oct 10.

PMID:
27729108
17.

[Diagnosis and follow-up observation of granulosa cell tumor of the ovary are becoming more precise].

Färkkilä A, Unkila-Kallio L.

Duodecim. 2016;132(11):1033-9. Review. Finnish.

PMID:
27400589
18.

Molecularly Defined Adult Granulosa Cell Tumor of the Ovary: The Clinical Phenotype.

McConechy MK, Färkkilä A, Horlings HM, Talhouk A, Unkila-Kallio L, van Meurs HS, Yang W, Rozenberg N, Andersson N, Zaby K, Bryk S, Bützow R, Halfwerk JB, Hooijer GK, van de Vijver MJ, Buist MR, Kenter GG, Brucker SY, Krämer B, Staebler A, Bleeker MC, Heikinheimo M, Kommoss S, Blake Gilks C, Anttonen M, Huntsman DG.

J Natl Cancer Inst. 2016 Jun 13;108(11). pii: djw134. doi: 10.1093/jnci/djw134. Print 2016 Nov. Erratum in: J Natl Cancer Inst. 2017 Apr 1;109(4):.

19.

[Heterotopic pregnancy during the second trimester is a severe complication of pregnancy].

Färkkilä A, Laitinen L.

Duodecim. 2016;132(8):730-3. Finnish.

PMID:
27244932
20.

GATA factors in endocrine neoplasia.

Pihlajoki M, Färkkilä A, Soini T, Heikinheimo M, Wilson DB.

Mol Cell Endocrinol. 2016 Feb 5;421:2-17. doi: 10.1016/j.mce.2015.05.027. Epub 2015 May 28. Review.

21.

The clinical utility of serum anti-Müllerian hormone in the follow-up of ovarian adult-type granulosa cell tumors--A comparative study with inhibin B.

Färkkilä A, Koskela S, Bryk S, Alfthan H, Bützow R, Leminen A, Puistola U, Tapanainen JS, Heikinheimo M, Anttonen M, Unkila-Kallio L.

Int J Cancer. 2015 Oct 1;137(7):1661-71. doi: 10.1002/ijc.29532. Epub 2015 Apr 11.

22.

Clinical characteristics and survival of patients with an adult-type ovarian granulosa cell tumor: a 56-year single-center experience.

Bryk S, Färkkilä A, Bützow R, Leminen A, Heikinheimo M, Anttonen M, Riska A, Unkila-Kallio L.

Int J Gynecol Cancer. 2015 Jan;25(1):33-41. doi: 10.1097/IGC.0000000000000304.

PMID:
25347095
23.

HER2 and GATA4 are new prognostic factors for early-stage ovarian granulosa cell tumor-a long-term follow-up study.

Färkkilä A, Andersson N, Bützow R, Leminen A, Heikinheimo M, Anttonen M, Unkila-Kallio L.

Cancer Med. 2014 Jun;3(3):526-36. doi: 10.1002/cam4.230. Epub 2014 Mar 29.

24.

Sensitivity of human granulosa cell tumor cells to epidermal growth factor receptor inhibition.

Andersson N, Anttonen M, Färkkilä A, Pihlajoki M, Bützow R, Unkila-Kallio L, Heikinheimo M.

J Mol Endocrinol. 2014 Mar 12;52(2):223-34. doi: 10.1530/JME-13-0286. Print 2014 Apr.

PMID:
24463098
25.

FOXL2, GATA4, and SMAD3 co-operatively modulate gene expression, cell viability and apoptosis in ovarian granulosa cell tumor cells.

Anttonen M, Pihlajoki M, Andersson N, Georges A, L'hôte D, Vattulainen S, Färkkilä A, Unkila-Kallio L, Veitia RA, Heikinheimo M.

PLoS One. 2014 Jan 9;9(1):e85545. doi: 10.1371/journal.pone.0085545. eCollection 2014.

26.

Serum vascular endothelial growth factor A (VEGF) is elevated in patients with ovarian granulosa cell tumor (GCT), and VEGF inhibition by bevacizumab induces apoptosis in GCT in vitro.

Färkkilä A, Pihlajoki M, Tauriala H, Bützow R, Leminen A, Unkila-Kallio L, Heikinheimo M, Anttonen M.

J Clin Endocrinol Metab. 2011 Dec;96(12):E1973-81. doi: 10.1210/jc.2011-1812. Epub 2011 Oct 12.

PMID:
21994955
27.

Anti-Müllerian hormone inhibits growth of AMH type II receptor-positive human ovarian granulosa cell tumor cells by activating apoptosis.

Anttonen M, Färkkilä A, Tauriala H, Kauppinen M, Maclaughlin DT, Unkila-Kallio L, Bützow R, Heikinheimo M.

Lab Invest. 2011 Nov;91(11):1605-14. doi: 10.1038/labinvest.2011.116. Epub 2011 Aug 1.

28.

Vascular endothelial growth factor (VEGF) and its receptor VEGFR-2 are highly expressed in ovarian granulosa cell tumors.

Färkkilä A, Anttonen M, Pociuviene J, Leminen A, Butzow R, Heikinheimo M, Unkila-Kallio L.

Eur J Endocrinol. 2011 Jan;164(1):115-22. doi: 10.1530/EJE-10-0849. Epub 2010 Nov 1.

PMID:
21041381
29.

Vascular endothelial growth factor-C accelerates diabetic wound healing.

Saaristo A, Tammela T, Farkkilā A, Kärkkäinen M, Suominen E, Yla-Herttuala S, Alitalo K.

Am J Pathol. 2006 Sep;169(3):1080-7.

30.

Disturbance of the water and electrolyte balance during high-dose interferon treatment.

Färkkilä AM, Iivanainen MV, Färkkilä MA.

J Interferon Res. 1990 Apr;10(2):221-7.

PMID:
2341751
31.

Low platelet arachidonic acid in young patients with brain infarction.

Färkkilä MA, Rasi V, Tilvis RS, Ikkala E, Viinikka L, Ylikorkala O, Färkkilä AM, Miettinen TA.

Thromb Res. 1987 Dec 15;48(6):721-7.

PMID:
2829382

Supplemental Content

Loading ...
Support Center